Uus-Meremaa - inglise - Medsafe (Medicines Safety Authority)

max health limited - cefalexin monohydrate 26.295 mg/ml equivalent to cefalexin 25mg/ml;   - granules for oral suspension - 125 mg/5ml - active: cefalexin monohydrate 26.295 mg/ml equivalent to cefalexin 25mg/ml   excipient: allura red ac dimeticone imitation guarana flavour 051880 tp0551 methylcellulose pregelatinised maize starch sodium laurilsulfate sucrose xanthan gum - cefalexin is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: - bacterial sinusitis caused by streptococci, s. pneumoniae, and staphylococcus aureus (methicillin -sensitive only); - respiratory tract infections caused by s. pneumoniae and s. pyogenes (penicillin is the usual medicine of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever - cefalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefalexin in the subsequent prevention of either rheumatic fever or bacterial endocarditis are not available at present); - otitis media due to s. pneumoniae, h. influenzae, staphylococci, streptococci, and m. catarrhalis; - skin and skin-structure infections caused by staphylococci and/or streptococci; - bone infections caused by staphylococci and/or p. mirabilis; - genitourinary tract infections, including acute prostatitis, caused by e. coli, p. mirabilis, and klebsiella pneumoniae; - dental infections caused by staphylococci and/or streptococci. note - culture and susceptibility tests should be initiated prior to and during therapy. renal function studies should be performed when indicated.

Uus-Meremaa - inglise - Medsafe (Medicines Safety Authority)

max health limited - cefalexin monohydrate 52.591 mg/ml equivalent to cefalexin 50mg/ml;   - granules for oral suspension - 250 mg/5ml - active: cefalexin monohydrate 52.591 mg/ml equivalent to cefalexin 50mg/ml   excipient: allura red ac dimeticone imitation guarana flavour 051880 tp0551 methylcellulose pregelatinised maize starch sodium laurilsulfate sucrose xanthan gum - cefalexin is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: - bacterial sinusitis caused by streptococci, s. pneumoniae, and staphylococcus aureus (methicillin -sensitive only); - respiratory tract infections caused by s. pneumoniae and s. pyogenes (penicillin is the usual medicine of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever - cefalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefalexin in the subsequent prevention of either rheumatic fever or bacterial endocarditis are not available at present); - otitis media due to s. pneumoniae, h. influenzae, staphylococci, streptococci, and m. catarrhalis; - skin and skin-structure infections caused by staphylococci and/or streptococci; - bone infections caused by staphylococci and/or p. mirabilis; - genitourinary tract infections, including acute prostatitis, caused by e. coli, p. mirabilis, and klebsiella pneumoniae; - dental infections caused by staphylococci and/or streptococci. note - culture and susceptibility tests should be initiated prior to and during therapy. renal function studies should be performed when indicated.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - cefalexin monohydrate, quantity: 550 mg (equivalent: cefalexin, qty 500 mg) - capsule, hard - excipient ingredients: iron oxide yellow; gelatin; sunset yellow fcf; titanium dioxide; magnesium stearate; lactose monohydrate; brilliant blue fcf; purified water; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of the following bacterial infections when caused by susceptible strains of the designated micro-organisms. respiratory tract infections; strep. pneumoniae and group a b-haemolytic streptococci. although penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections (including the prophylaxis of rheumatic fever), cephalexin is generally effective in the eradication of streptococci from the nasopharynx. substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present. bacterial sinusitis: streptococci, strep. pneumoniae and staph. aureus (methicillin sensitive only). otitis media: strep. pneumoniae, staphylococci (methicillin sensitive only). skin and skin structure infections: staphylococci (methicillin sensitive only) and/or streptococci. genitourinary tract infections, including acute prostatitis: e.coli, p.mirabilis, and klebsiella sp. the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and genrx cephalexin is not indicated in these conditions. note. appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to genrx cephalexin. renal function studies should be perfomed when indicated.

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

dowelhurst ltd - cefalexin - oral capsule - 500mg

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - cefalexin - oral tablet - 500mg

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - cefalexin - oral tablet - 500mg

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - cefalexin - oral tablet - 500mg

Uus-Meremaa - inglise - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - cefalexin monohydrate 262.9mg equivalent to cephalexin 250 mg;   - capsule - 250 mg - active: cefalexin monohydrate 262.9mg equivalent to cephalexin 250 mg   excipient: gelatin   magnesium stearate microcrystalline cellulose titanium dioxide   water  

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - cefalexin - oral capsule - 250mg

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - cefalexin - oral capsule - 250mg